Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisacodyl + 2 L PEG-CS versus 4 L PEG for bowel cleansing in inflammatory bowel disease patients undergoing colonoscopy
2012-004214-34Phase 4Active
- Sponsor
- Luigi Sacco University Hospital
- Start
- Nov 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease comparing Bisacodyl + PEG-CS 2 L with PEG 4 L (2 arms). Primary endpoint: Degree of colon cleansing. Started Nov 2012; status: active.
02
Drugs
bisacodylmacrogol
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2012-004214-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004214-34.